From Zero to Enterprise: Aclid’s Playbook for Landing Early Customers in Regulated Markets

Landing early customers in regulated markets isn’t just about having a great product—it’s about finding the right entry point. In a recent episode of Category Visionaries, Aclid founder Kevin Flyangolts revealed their systematic approach to acquiring customers in the highly regulated biosecurity space.

The Power of Deep Customer Discovery

While many startups rush to build, Aclid took a different approach. “We spent probably the first three months talking to 40 to 60 different manufacturers and just learning, figuring out what it is that they do day to day,” Kevin explains. “Where are the biggest pain points? Is it in the screening? Is it in the vetting of the customer? Is it somewhere totally else?”

This wasn’t just market research—it was a strategic effort to understand the nuances of their potential customers’ operations. The process revealed that many manufacturers were struggling with manual compliance processes, creating an opportunity for automation.

Finding the Right Entry Point

A crucial insight emerged from these conversations: while large manufacturers had built internal systems, early-stage companies were drowning in compliance requirements. “When you’re an early stage company, you are dealing with a lot of problems,” Kevin notes. “If you’re starting a company that requires facilities, 50 people, just to get started, just to build your first product and sell it to a customer, there’s just that much more. And dealing with compliance burdens along that way makes it that much harder.”

This realization led to a counterintuitive strategy. Instead of targeting the biggest players, Aclid focused on early-stage manufacturers who lacked the resources to build comprehensive compliance systems.

Building the Right Strategic Partnerships

Credibility was crucial for landing those first customers. Aclid’s partnership with Professor Harris Wong of Columbia University proved invaluable. “Harris is pretty established researcher,” Kevin explains. “He has a big name in the industry… So definitely a lot of intros, warm connections from him helped build some of that trust.”

This combination of technical expertise and academic credibility helped open doors that might have remained closed to a typical startup.

Converting Pain into Solutions

The depth of their customer discovery process allowed Aclid to identify specific operational bottlenecks. They found manufacturers were “calling up a customer, avoid having to screen their order and look at what’s inside.” This manual process was both inefficient and risky.

Aclid’s solution automated these processes end-to-end, helping manufacturers verify “that they have the right permissions, the right facilities and the right documents to actually ship the order and do it without any type of liability or risk of non compliance.”

The Evolution to Enterprise

As Aclid proved their value with early-stage manufacturers, they began attracting attention from larger players. “Now we’re starting to work with some of the largest manufacturers in the space,” Kevin notes, “replacing their in house systems, making them more automated, and giving them their ability to focus back on the chemistry and the manufacturing, rather than on the administrative burden of compliance.”

Building for Market Evolution

Timing also played a crucial role in their strategy. Launching during the pandemic, when “security was top of mind,” Aclid positioned themselves at the intersection of innovation and safety. Their approach paralleled emerging discussions around AI regulation: “Similar to kind of what’s happening with AI now, with government taking a precautionary measure and starting to look at it much more carefully ahead of problems actually being there.”

For founders entering regulated markets, Aclid’s journey offers valuable lessons. Start with deep customer discovery, focus on acute pain points where your value proposition is clearest, and build strategic partnerships that enhance credibility. Most importantly, look for market segments where the pain is so severe that customers are willing to take a chance on a startup solution.